SRR1328919
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.359
- MYOGENESIS+0.321
- ADIPOGENESIS+0.311
- FATTY_ACID_METABOLISM+0.304
- IL6_JAK_STAT3_SIGNALING+0.268
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.251
- ESTROGEN_RESPONSE_LATE+0.231
- XENOBIOTIC_METABOLISM+0.231
- KRAS_SIGNALING_DN+0.220
- COAGULATION+0.213
Top 10 suppressed
- MYC_TARGETS_V2-0.505
- MYC_TARGETS_V1-0.502
- G2M_CHECKPOINT-0.468
- E2F_TARGETS-0.446
- DNA_REPAIR-0.442
- UNFOLDED_PROTEIN_RESPONSE-0.420
- WNT_BETA_CATENIN_SIGNALING-0.369
- TGF_BETA_SIGNALING-0.306
- CHOLESTEROL_HOMEOSTASIS-0.284
- MITOTIC_SPINDLE-0.254
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1430570 | GTEX | — | 0.911 |
| 2 | BS_ARBQDTT5 | pilocytic astrocytoma | — | 0.910 |
| 3 | SRR1399092 | GTEX | — | 0.906 |
| 4 | SRR1365828 | GTEX | — | 0.901 |
| 5 | ERR2598329 | fetal | fetal | 0.894 |
| 6 | SRR656167 | GTEX | — | 0.891 |
| 7 | ERR2598267 | fetal | fetal | 0.872 |
| 8 | ERR2598266 | fetal | fetal | 0.869 |
| 9 | SRR1459211 | GTEX | — | 0.856 |
| 10 | BS_PKW05VZV | high-grade glioma | — | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.359 | Inavolisib | — uncovered |
| MYOGENESIS | 0.321 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.311 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.304 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.268 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.251 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.231 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.231 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| COAGULATION | 0.213 | Binimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.209 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.183 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.178 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.168 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.166 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.164 | Inavolisib | — uncovered |
| APOPTOSIS | 0.159 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.159 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.154 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.147 | Idelalisib | — uncovered |